Literature DB >> 19239199

Interaction between the N- and C-terminal domains modulates the stability and lipid binding of apolipoprotein A-I.

Mao Koyama1, Masafumi Tanaka, Padmaja Dhanasekaran, Sissel Lund-Katz, Michael C Phillips, Hiroyuki Saito.   

Abstract

The tertiary structures of human and mouse apolipoprotein A-I (apoA-I) are comprised of an N-terminal helix bundle and a separate C-terminal domain. To define the possible intramolecular interaction between the N- and the C-terminal domains, we examined the effects on protein stability and lipid-binding properties of exchanging either the C-terminal domain or helix between human and mouse apoA-I. Chemical denaturation experiments demonstrated that replacement of the C-terminal domain or helical segment in human apoA-I with the mouse counterparts largely destabilizes the N-terminal helix bundle. Removal of the C-terminal domain or alpha-helix in human apoA-I had a similar effect on the destabilization of the helix bundle against urea denaturation, indicating that the C-terminal helical segment mainly contributes to stabilizing the N-terminal helix bundle structure in the apoA-I molecule. Consistent with this, KI quenching experiments indicated that removal or replacement of the C-terminal domain or helix in human apoA-I causes Trp residues in the N-terminal domain to become exposed to solvent. Measurements of the heats of binding to egg phosphatidylcholine (PC) vesicles and the kinetics of solubilization of dimyristoyl PC vesicles demonstrated that the destabilized human N-terminal helix bundle can strongly interact with lipids without the hydrophobic C-terminal helix. In addition, site-specific labeling of the N- and C-terminal helices by acrylodan to probe the conformational stability and the spatial proximity of the two domains indicated that the C-terminal helix is located near the N-terminal helix bundle, leading to a relatively less solvent-exposed, more organized conformation of the C-terminal domain. Taken together, these results suggest that interaction between the N- and C-terminal tertiary structure domains in apoA-I modulates the stability and lipid-binding properties of the N-terminal helix bundle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239199      PMCID: PMC2936823          DOI: 10.1021/bi802317v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  64 in total

Review 1.  The structural basis for amyloid formation by plasma apolipoproteins: a review.

Authors:  Danny M Hatters; Geoffrey J Howlett
Journal:  Eur Biophys J       Date:  2002-03       Impact factor: 1.733

2.  Conformational changes of an exchangeable apolipoprotein, apolipophorin III from Locusta migratoria, at low pH: correlation with lipid binding.

Authors:  P M Weers; C M Kay; R O Ryan
Journal:  Biochemistry       Date:  2001-06-26       Impact factor: 3.162

3.  Structural organization of the N-terminal domain of apolipoprotein A-I: studies of tryptophan mutants.

Authors:  W S Davidson; K Arnvig-McGuire; A Kennedy; J Kosman; T L Hazlett; A Jonas
Journal:  Biochemistry       Date:  1999-10-26       Impact factor: 3.162

Review 4.  The effects of altered apolipoprotein A-I structure on plasma HDL concentration.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  Trends Cardiovasc Med       Date:  2002-04       Impact factor: 6.677

5.  Folding and stability of the C-terminal half of apolipoprotein A-I examined with a Cys-specific fluorescence probe.

Authors:  Andrea K Behling Agree; M Alejandra Tricerri; Kirsten Arnvig McGuire; Shao-min Tian; Ana Jonas
Journal:  Biochim Biophys Acta       Date:  2002-02-11

6.  Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles.

Authors:  H Saito; P Dhanasekaran; F Baldwin; K H Weisgraber; S Lund-Katz; M C Phillips
Journal:  J Biol Chem       Date:  2001-08-30       Impact factor: 5.157

7.  Characterization of apolipoprotein A-I structure using a cysteine-specific fluorescence probe.

Authors:  M A Tricerri; A K Behling Agree; S A Sanchez; A Jonas
Journal:  Biochemistry       Date:  2000-11-28       Impact factor: 3.162

8.  Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization.

Authors:  Mark L Segall; Padmaja Dhanasekaran; Faye Baldwin; G M Anantharamaiah; Karl H Weisgraber; Michael C Phillips; Sissel Lund-Katz
Journal:  J Lipid Res       Date:  2002-10       Impact factor: 5.922

9.  ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity.

Authors:  Márcia Almeida Liz; Cláudio M Gomes; Maria João Saraiva; Mónica Mendes Sousa
Journal:  J Lipid Res       Date:  2007-08-10       Impact factor: 5.922

10.  Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease.

Authors:  Julie A Morrow; Danny M Hatters; Bin Lu; Peter Hochtl; Keith A Oberg; Bernhard Rupp; Karl H Weisgraber
Journal:  J Biol Chem       Date:  2002-10-21       Impact factor: 5.157

View more
  31 in total

1.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

2.  Fluorescence analysis of the lipid binding-induced conformational change of apolipoprotein E4.

Authors:  Chiharu Mizuguchi; Mami Hata; Padmaja Dhanasekaran; Margaret Nickel; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2012-07-03       Impact factor: 3.162

3.  Impact of self-association on function of apolipoprotein A-I.

Authors:  Shobini Jayaraman; Sumiko Abe-Dohmae; Shinji Yokoyama; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

4.  Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice.

Authors:  Eric T Alexander; Charulatha Vedhachalam; Sandhya Sankaranarayanan; Margarita de la Llera-Moya; George H Rothblat; Daniel J Rader; Michael C Phillips
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

5.  Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  Biochemistry       Date:  2011-02-20       Impact factor: 3.162

6.  The roles of C-terminal helices of human apolipoprotein A-I in formation of high-density lipoprotein particles.

Authors:  Kohjiro Nagao; Mami Hata; Kento Tanaka; Yuki Takechi; David Nguyen; Padmaja Dhanasekaran; Sissel Lund-Katz; Michael C Phillips; Hiroyuki Saito
Journal:  Biochim Biophys Acta       Date:  2013-10-09

7.  Structure of apolipoprotein A-I N terminus on nascent high density lipoproteins.

Authors:  Jens O Lagerstedt; Giorgio Cavigiolio; Madhu S Budamagunta; Ioanna Pagani; John C Voss; Michael N Oda
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

8.  Influence of N-terminal helix bundle stability on the lipid-binding properties of human apolipoprotein A-I.

Authors:  Masafumi Tanaka; Padmaja Dhanasekaran; David Nguyen; Margaret Nickel; Yuki Takechi; Sissel Lund-Katz; Michael C Phillips; Hiroyuki Saito
Journal:  Biochim Biophys Acta       Date:  2010-10-30

Review 9.  The helix bundle: a reversible lipid binding motif.

Authors:  Vasanthy Narayanaswami; Robert S Kiss; Paul M M Weers
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2009-09-19       Impact factor: 2.320

10.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.